gevokizumab + bevacizumab + modified FOLFOX6

A combination regimen consisting of **gevokizumab**, **bevacizumab**, and **modified FOLFOX6** used in oncology clinical trials, particularly for advanced or metastatic cancer. Gevokizumab is a monoclonal antibody that targets interleukin-1 beta (IL-1β), modulating inflammatory responses. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing angiogenesis. Modified FOLFOX6 is a chemotherapy regimen containing oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil, designed to interrupt DNA replication and repair in rapidly dividing cancer cells. The combination is investigated for synergistic efficacy by combining anti-inflammatory, anti-angiogenic, and cytotoxic mechanisms.